Targeted therapies, however, have had a greater impact thus far because, for the subset of lung cancer patients with driver mutations (often nonsmokers), persistent response and survival extension therapy are targeted to EGFR, ALK, RAF, ROS, RET, and HER2. This evidence concerns the gene EGFR and lung carcinoma.